GOSS Gossamer Corp: Forward P/S Multiple
Gossamer Bio, Inc. (GOSS) is developing targeted therapy for pulmonary hypertension, aiming to eliminate the root causes of the pathology. The forward P/S history confirms this potential, with the metric currently standing at 0.90. Growth is driven by the chemists' flexible approach and equity-based incentives for personnel, although the lack of commercial products leaves the company dependent on external financing during the clinical testing phase.
Analytical breakdowns for Gossamer Bio, Inc.
- current price and projected stock value:
- company stock capitalization data:
- issuer book value statistics:
- debt and liquidity details:
Debt to Equity Gossamer Bio, Inc.|GOSS - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Capital Gossamer Bio, Inc.|GOSS - Company Aggregate Debts|Debt to Book Capitalization Ratio Gossamer Bio Corp.|GOSS - Company Long-Term Liabilities|Company Short-Term Debts Gossamer Bio|Quick Liquidity gossamerbio.com
- business earnings and investment ratios data:
GOSS - Final Profit|Future Profit Gossamer Bio, Inc.|GOSS - Company Value to Net Income|Forward P/E Multiple Gossamer Corp|GOSS - Price/Earnings to Growth Ratio|EV/EBITDA Multiple Gossamer Bio Corp.|GOSS - Operating income before deduction of amortization|Earnings per share for the last twelve months Gossamer Bio|GOSS - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months gossamerbio.com|GOSS - Earnings per share increase in current year|Earnings growth forecast for next year Gossamer Bio, Inc.
- revenue and sales details:
Fundamental company analysis:GOSS (Gossamer Bio)
The logistics efficiency of biotechnological substances directly impacts the future cash flows of Gossamer Bio, Inc. (GOSS). This metric compares the current market value of the business with expected revenue based on analyst forecasts. By analyzing the forward P/S trajectory, an investor determines the degree of stock overvaluation relative to potential sales. This allows for balancing the risk of a capitalization collapse against the actual commercialization rates of drugs for the treatment of pulmonary pathologies.
Competitors of Gossamer Bio, Inc. (GOSS)
Forward P/S Multiple ARGX (argenx)|BioNTech Inc. (BNTX) - Market Cap to Future Revenue Ratio|Abivax Corp - Forward P/S Multiple|Projected Price to Revenue ADMA Corp (ADMA)|Protagonist Therapeutics (PTGX) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio immunovant.com (IMVT)|Price-to-Projected Revenue Ratio Kiniksa|Grifols SA (GRFS) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Adaptive Biotechnologies Corp (ADPT)|Market Cap to Expected Sales Ratio Celldex Corp|Forward P/S Multiple AUPH (Aurinia Pharmaceuticals)|Forward P/S Multiple biocryst.com BCRX|VERA - Price-to-Projected Revenue Ratio|Dianthus Therapeutics Inc (DNTH) - Forward Price-to-Revenue Multiple|PHVS: Forward P/S Multiple|Market Cap to Future Revenue Ratio AbCellera Corp (ABCL)|Price-to-Projected Revenue Ratio Tourmaline Bio, Inc.|PGEN: Forward Price to Sales|Forward Price-to-Revenue Multiple PHAR (Pharming Group)|NKTR (Nektar Therapeutics Inc) - Forward Price to Sales|Forward P/S Multiple UPB (Upstream Bio Corp)|Zenas Corp - Price-to-Projected Revenue Ratio|Immunome, Inc. - Forward P/S Multiple|Market Cap to Expected Sales Ratio kalvista.com KALV|Septerna (SEPN) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Pieris Pharma (PVLA)|Forward Price-to-Revenue Multiple SVRA|RIGL: Forward Price to Sales|Forward P/S Multiple ANAB|Market Cap to Expected Sales Ratio astriatx.com|Price-to-Projected Revenue Ratio enGene ENGN|RAPT: Market Cap to Projected Revenue|Aerovate - Forward P/S Multiple|Aclaris Therapeutics, Inc (ACRS) - Forward Price-to-Revenue Multiple|KYTX (Kyverna Therapeutics) - Forward Price-to-Revenue Multiple|TLSA - Market Cap to Expected Sales Ratio|CABA (Cabaletta Bio) - Forward P/S Multiple|VTYX - Projected Price to Revenue|Price-to-Projected Revenue Ratio Theratechnologies Inc (THTX)|AVTX - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Eledon Pharmaceuticals ELDN|Market Cap to Expected Sales Ratio agenusbio.com (AGEN)|CLYM - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Zura Bio Ltd ZURA|aTyr (ATYR) - Price-to-Projected Revenue Ratio|Future Price to Revenue ADAG (Adagene Inc.)|IMA (ImageneBio) - Forward P/S Multiple|STTK: Forward Price to Sales|Forward P/S Multiple EQ|Forward P/S Multiple connectbiopharm.com (CNTB)|Price-to-Projected Revenue Ratio Immunic IMUX|Forward Price to Sales ATRA|IFRX - Price-to-Projected Revenue Ratio|x4pharma.com (XFOR) - Forward Price-to-Revenue Multiple|ACET: Forward P/S Multiple|Celularity (CELU) - Forward P/S Multiple|Forward Price-to-Revenue Multiple INMB|BRNS: Forward Price to Sales|Forward P/S Multiple KZR|Market Cap to Expected Sales Ratio sabbiotherapeutics.com|Price-to-Projected Revenue Ratio Akari Therapeutics Plc AKTX|ENLV - Forward Price-to-Revenue Multiple|QTTB - Price-to-Projected Revenue Ratio|GeoVax Corp (GOVX) - Forward Price-to-Revenue Multiple|EDSA (Edesa Biotech, Inc.) - Forward Price-to-Revenue Multiple|ibioinc.com (IBIO) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Carisma Therapeutics Inc|Market Cap to Projected Revenue XTLB (XTL Biopharmaceuticals Ltd)|Forward P/S Multiple BOLT|HCWB - Market Cap to Future Revenue Ratio|Forward P/S Multiple APVO (Aptevo Therapeutics Inc.)|Projected Price to Revenue AIM ImmunoTech, Inc.|ADTX - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio GRI Bio Inc|XORTX (XRTX) - Price-to-Projected Revenue Ratio|HIND - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Revelation Biosciences|indaptusrx.com (INDP) - Market Cap to Expected Sales Ratio|Forward P/S Multiple SCNI|Forward P/S Multiple calcimedica.com (CALI)|Price-to-Projected Revenue Ratio Affimed N.V. AFMD|ALLK - Forward Price-to-Revenue Multiple|HOOKIPA - Forward P/S Multiple|Market Cap to Future Revenue Ratio IGM Biosciences, Inc.|iTeos Therapeutics, Inc. (ITOS) - Price-to-Projected Revenue Ratio|Ocean Biomedical Inc - Forward Price to Sales|Forward Price-to-Revenue Multiple TCBP|THRD: Forward Price to Sales
